Article
Histopathologic characteristics of therapy-associated cutaneous neoplasms with vemurafenib, a selective BRAF kinase inhibitor, used in the treatment of melanoma.
Journal of cutaneous pathology - 1 Jul 2014
Sufficool Kari E, Hepper Donna M, Linette Gerald P, Hurst Eva A, Lu Dongsi, Lind Anne C, Cornelius Lynn A
Abstract excerpt
BACKGROUND: Activating mutations in BRAF have been observed in up to 60% of melanomas, indicating a pivotal role for kinase deregulation in tumor progression. Vemurafenib is a specific inhibitor of BRAF for treatment of melanomas with activating BRAF V600E mutations and has been a major advancement in melanoma treatment. Treatment with vemurafenib, and to a lesser extent, sorafenib, a relatively non-specific...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.